Analyst Reco. Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Real-time Estimate Cboe BZX Other stock markets 07:00:09 29/04/2024 pm IST			5-day change	1st Jan Change
0.525 ^USD	+1.39%		+1.23%	-4.69%

22/03	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
14/03	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Downgrades Sangamo Therapeutics to Hold From Buy	07/11	MT
HC Wainwright Cuts Price Target on Sangamo Therapeutics to $3 From $5, Maintains Buy Rating	06/11	MT
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight From Overweight, Price Target is $1	06/11	MT
Wedbush Lowers Sangamo Therapeutics' PT to $2 From $10 as Result of Valuing Potential Royalty From ST-920 Sales, Keeps Outperform Rating	03/11	MT
RBC Downgrades Sangamo Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Cites 'Cash Preservation Mode,' Keeps Speculative Risk	03/11	MT
Truist Securities Adjusts Price Target on Sangamo Therapeutics to $7 From $8, Maintains Buy Rating	15/23/15	MT
Wedbush Lowers Sangamo Therapeutics' Price Target to $10 From $16, Keeps Outperform Rating	11/23/11	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $4 From $5, Maintains Overweight Rating	10/23/10	MT
Barclays Lowers Sangamo Therapeutics' Price Target to $9 From $11, Overweight Rating Maintained	09/23/09	MT
RBC Cuts Price Target on Sangamo Therapeutics to $6 From $8, Keeps Outperform, Speculative Risk	09/23/09	MT
Truist Adjusts Price Target on Sangamo Therapeutics to $8 From $16, Keeps Buy Rating	10/23/10	MT
HC Wainwright Adjusts Sangamo Therapeutics' Price Target to $5 From $15, Keeps Buy Rating	01/23/01	MT
RBC Capital Adjusts Sangamo Therapeutics Price Target to $8 From $13, Maintains Outperform - Speculative Risk Rating	06/23/06	MT
HC Wainwright Adjusts Sangamo Therapeutics Price Target to $15 From $25, Maintains Buy Rating	03/23/03	MT
Wedbush Upgrades Sangamo Therapeutics to Outperform From Neutral, Raises Price Target to $16 From $4	27/23/27	MT
RBC Capital Adjusts Price Target on Sangamo Therapeutics to $13 From $22, Maintains Outperform Rating	23/23/23	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $15 From $20, Maintains Overweight Rating	04/23/04	MT
Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $20 From $22, Maintains Overweight Rating	07/22/07	MT
Wedbush Adjusts Sangamo Therapeutics' Price Target to $4 From $5 After Increase in Share Count, Keeps Neutral Rating	07/22/07	MT
Truist Trims Price Target for Sangamo Therapeutics to $17 From $19, Maintains Buy Rating	08/22/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Analyst Reco.

Filters